A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: SHR6390|DRUG: Letrozole or anastrozole or Fulvestrant
Sponsor: Jiangsu HengRui Medicine Co., Ltd.